Today, SolaranRx, Inc. announced that US health regulators have granted orphan drug designation to its lead drug candidate in development for skin cancer. The “theranostics” – the merger between therapeutics and diagnostics – company said that the US Food and Drug Administration (FDA) has granted Orphan Drug status to its …